E3 Ligase Ligand 2

E3 ligase ligand 2 is an active metabolite of thalidomide (Cay-14610) and an intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs) containing thalidomide, a ligand for the E3 ubiquitin ligase cereblon (CRBN), used in targeted protein degradation. E3 ligase ligand 2 is formed from thalidomide via hydroxylation. It decreases the production of TNF-alpha induced by 12-O-tetradecanoylphorbol 13-acetate (TPA, Cay-10008014) in THP-1 cells when used at a concentration of 30 µM. E3 ligase ligand 2 (333 µM) completely inhibits the proliferation of human umbilical vein endothelial cells (HUVECs). It inhibits VEGF- and FGF2-induced angiogenesis by 14% in a chicken chorioallantoic membrane (CAM) assay in utero when administered at a dose of 100 µg/embryo.Formal Name: 2-(2,6-dioxo-3-piperidinyl)-4-hydroxy-1H-isoindole-1,3(2H)-dione. CAS Number: 5054-59-1. Synonyms: 4-hydroxy Thalidomide. Molecular Formula: C13H10N2O5. Formula Weight: 274.2. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMF: 12 mg/ml, DMSO: 10 mg/ml. lambdamax: 220 nm. SMILES: O=C1C2=C(C(N1C3C(NC(CC3)=O)=O)=O)C(O)=CC=C2. InChi Code: InChI=1S/C13H10N2O5/c16-8-3-1-2-6-10(8)13(20)15(12(6)19)7-4-5-9(17)14-11(7)18/h1-3,7,16H,4-5H2,(H,14,17,18). InChi Key: XMPJICVFSDYOEG-UHFFFAOYSA-N.